DaVita reports progress in value-based kidney care programs

DaVita reported a 9% improvement in its Total Quality Score through 2024 and has delivered >$200M in shared savings under the CKCC program, underscoring operational gains in value-based kidney care. Q4 2025 EPS beat at $3.40 vs $3.24 and revenue beat at $3.62B vs $3.51B; shares are up ~32% YTD and the stock trades near a 52-week high ($159.42) with UBS raising its PT to $190 (from $186). Management targets ~2% long-term volume growth and the company manages >$5B in medical costs under value-based arrangements, supporting a constructive fundamental outlook.

Analysis

The structural shift from fee-for-service to risk-based kidney care creates a more predictable, recurring cash flow profile for an operator that can scale care-management infrastructure; that predictability compresses revenue volatility and creates optionality to monetize care management (e.g., risk corridors, MSO/IPA-style deals, or carve-outs). Second-order, this makes the company a potential consolidator/partner for nephrology groups and transplant centers—transactions that trade on service continuity and patient-steering economics rather than simple dialysis unit counts.

On the supply side, lower in-center utilization per patient but higher per-patient care touchpoints favors companies that sell clinical software, care-coordination services and higher-margin ancillary offerings over pure consumables suppliers. Expect margin divergence vs. dialysis-equipment and consumables vendors as payers pressure unit reimbursements while paying for avoided downstream spends (hospitalizations, ER visits) — a multi-quarter reallocation of procurement spend is plausible.

Primary tail risks are policy/regulatory changes to CMS shared-savings rules and the durability of physician partnerships; both can flip profitability quickly if shared-savings pools shrink or attribution rules tighten. Near-term catalysts to watch are CMS rule publications, large partner renewals/terminations, and quarterly guidance cadence — these will drive 3–12 month volatility, while transplants and true clinical outcome shifts play out over 2–4 years.

Contrarian lens: consensus may underweight the company’s optionality to spin or license care-management platforms (implies underappreciated upside) but may also overestimate the sustainability of outsized shared-savings in a more crowded value-based landscape. Monitor partner concentration and the margin mix of fee-for-service vs. risk-based revenue to adjudicate which view is winning.

Key Decisions for Investors

• Long DVA (6–12 month horizon): initiate a 2–4% portfolio position sized to target asymmetric upside from re-rating (+25–40%) if care-management commercialization continues; use a hard stop at -18% to limit policy/regulatory shock losses.
• Buy a 9–12 month DVA call spread to cap cost: long a 25% OTM call / short a 60% OTM call (size to risk no more than 0.5–1% of portfolio). Rationale: captures re-rating on continued shared-savings momentum with defined downside (premium) and ~2–4x upside if outcomes/KPIs converge.
• Pair trade (12 month): long DVA / short FMS.DE (Fresenius Medical Care) in equal notional amounts to isolate U.S. value-based execution vs. global volume exposure — target relative outperformance of 15–25%; cut the pair if divergence reverses by >12% in 6 weeks.
• Income entry if comfortable owning (short-dated, 6–8 week): sell cash-secured puts at ~10–12% below current spot to collect premium and acquire equity at a discount; limit allocation so assignment does not exceed 3% portfolio exposure and be prepared to delta-hedge around regulatory headlines.